Monte Rosa Therapeutics, Inc. (GLUE)
13.78
-0.52
(-3.67%)
USD |
NASDAQ |
Aug 24, 16:00
13.77
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Shareholders Equity (Quarterly) : 487.28M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 487.28M |
| March 31, 2026 | 521.92M |
| December 31, 2025 | 233.06M |
| September 30, 2025 | 245.84M |
| June 30, 2025 | 268.08M |
| March 31, 2025 | 275.16M |
| December 31, 2024 | 222.94M |
| September 30, 2024 | 205.46M |
| June 30, 2024 | 224.67M |
| March 31, 2024 | 152.52M |
| December 31, 2023 | 179.25M |
| September 30, 2023 | 184.52M |
| Date | Value |
|---|---|
| June 30, 2023 | 213.65M |
| March 31, 2023 | 243.73M |
| December 31, 2022 | 271.41M |
| September 30, 2022 | 291.09M |
| June 30, 2022 | 302.05M |
| March 31, 2022 | 325.88M |
| December 31, 2021 | 347.52M |
| September 30, 2021 | 369.30M |
| June 30, 2021 | 356.68M |
| March 31, 2021 | -60.62M |
| December 31, 2020 | -48.73M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Nurix Therapeutics, Inc. | 402.63M |
| Gilead Sciences, Inc. | 11.83B |
| Ironwood Pharmaceuticals, Inc. | -161.84M |
| Capricor Therapeutics, Inc. | 246.22M |
| Cue Biopharma, Inc. | 2.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 691.16M |
| Total Liabilities (Quarterly) | 203.88M |
| Debt to Equity Ratio | 0.078 |
| Current Ratio | 10.58 |
| Net Debt Paydown Yield | 0.04% |